Reference number
1977-H

## SPECIALTY QUANTITY LIMIT PROGRAM

# **ORENCIA** (abatacept)

### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

#### **II. COVERED QUANTITIES**

Medication	FDA-recommended dosing	Standard Limit	Exception Limit
Orencia (abatacept) subcutaneous injection: 50 mg per 0.4 ml syringe	<ul> <li>RA and PsA (adult): 125 mg once weekly</li> <li>PJIA, weight 10 kg to &lt; 25 kg: 50 mg once weekly</li> <li>PJIA, weight 25 kg to &lt; 50 kg: 87.5 mg once weekly</li> <li>PJIA, weight ≥ 50 kg: 125 mg once weekly</li> </ul>	4 syringes per 28 days	N/A
Orencia (abatacept) subcutaneous injection: 87.5 mg per 0.7 ml syringe		4 syringes per 28 days	N/A
Orencia (abatacept) subcutaneous injection: 125 mg per ml syringe		4 syringes per 28 days	N/A
Orencia (abatacept) intravenous: 250 mg single-use vial	<ul> <li>RA and PsA (adult) at week 0, 2, and 4 then every 4 weeks</li> <li>Weight less than 60 kg: 500 mg</li> <li>Weight 60 kg to 100 kg: 750 mg</li> <li>Weight more than 100 kg: 1000 mg</li> <li>PJIA</li> <li>Weight less than 75 kg: 10 mg per kg</li> <li>Weight 75 kg or more: following the RA/PsA dosing above</li> </ul>	4 vials every 4 weeks	12 vials per 29 days*

Abbreviations: RA = rheumatoid arthritis; PsA = psoriatic arthritis; PJIA = polyarticular juvenile idiopathic arthritis

### III. REFERENCE

1. Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; June 2017.

Specialty Quantity Limit Orencia P2017b.docx

© 2017 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



<sup>\*</sup>Loading doses are addressed by the post-limit quantity exceptions criteria.